US FDA approves Granules Indias OTC equivalent of Advil Dual Action tablets

US FDA approves Granules Indias OTC equivalent of Advil Dual Action tablets

By, Admin 17 July 2023

Granules India Limited, a vertically integrated fast growing Indian pharmaceutical company, announced that the US Food & Drug Administration (FDA) has approved its Abbreviated New Drug Application (ANDA), filed by Granules Pharmaceuticals, Inc. (GPI), a wholly owned foreign subsidiary of the company, for acetaminophen and ibuprofen tablets, 250 mg/125 mg (OTC). It is bioequivalent to the reference listed drug (RLD), Advil Dual Action with acetaminophen tablets, 250mg/125 mg (OTC), of GlaxoSmithKline Consumer Healthcare Holdings (US) LLC. This product will be launched through the Granules Consumer Health (GCH) division. Acetaminophen and ibuprofen tablets are used for temporary relief of minor aches and pains due to headaches, toothaches, backaches, menstrual cramps, muscular aches, and minor arthritis pain. Granules has a total of 59 ANDA approvals from the US FDA (57 Final and 2 tentative approvals). According to IRI multi-outlet market data, the Advil Dual Action with acetaminophen tablets (OTC) brand and store brands had combined US sales of approximately $70 million in the most recent twelve months. Advil is a registered trademark of GlaxoSmithKline Consumer Healthcare Holdings (US). Granules India Limited, incorporated in 1991 is a vertically integrated fast growing Indian pharmaceutical company headquartered in Hyderabad with best-in-class facilities and a commitment to operational excellence, quality, and customer service. Amongst the few pharmaceutical companies in the world to be present across the manufacturing of the entire pharmaceutical value chain

Optimize Your trial insights with Clival Database.

Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.

Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.

With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.

To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.

Elevate your trial success rate with the cutting-edge insights from Clival database.

Check it out today and make more informed sourcing decisions! Learn More!